Skip to main content

Advertisement

Table 1 Baseline characteristics of the study population

From: Effect of low-dose spironolactone on resistant hypertension in type 2 diabetes mellitus: a randomized controlled trial in a sub-Saharan African population

  Spironolactone (n = 9) Alternative drug regimen (n = 8) p value
Sociodemographic and clinical characteristics
 Age (years) 64.6 (9.6) 61.0 (6.6) 0.15
 Sex (male/female) 3/6 5/3 0.34
 Smoking 0 0
 Alcoholic index (g/l) 0 0
 Body mass index (kg/m2) 30.3 (5.4) 30.5 (7.7) 0.95
 Waist circumference (cm) 104.8 (12.5) 102.7 (10.2) 0.74
 Office SBPa (mmHg) 158 (17) 158 (8) 0.96
 Office DBPa (mmHg) 86 (11) 94 (8) 0.08
 Office heart rate (beats/minute) 75 (12) 76 (1) 6 0.92
 Self-measured SBP (mmHg) 140 (9) 151 (15) 0.06
 Self-measured DBP (mmHg) 78 (8) 91 (15) 0.07
Biological parameters
 Fasting glycaemia (g/l) 182.89 (105.45) 141.13 (56.36) 0.33
 Glycatedhaemoglobin (%) 8.45 (1.76) 8.64 (2.43) 0.88
 Blood urea nitrogen (g/l) 0.48 (0.01) 0.48 (0.04) 0.96
 Serum creatinine (mg/l) 15.63 (5.97) 12.45 (3.41) 0.20
 eGFR (ml/min/1.73 m2) 55.25 (23.76) 73.99 (27.96) 0.15
 Serum potassium (mmol/l) 4.02 (0.15) 4.01 (0.10) 0.88
 Serum sodium (mmol/l) 140.5 (0.5) 141.0(0.7) 0.11
 Serum total cholesterol (g/l) 1.71 (0.39) 2.21 (1.00) 0.43
 Serum HDL-C (g/l) 0.58 (0.09) 0.35 (0.10) 0.06
 Serum LDL-C (g/l) 0.88 (0.35) 1.54 (1.20) 0.43
 Serum triglyceride (g/l) 1.32 (0.98) 1.63 (1.43) 0.90
 Proteinuria (number of +) 1.11 (1.6) 1 (1.06) 0.84
Complications
 Chronic kidney disease 9 (100) 8 (100)  
  1. Data are expressed as mean (standard deviations); no statistical difference was found for any of the parameters compared between the spironolactone and control groups; Alternative drug regimens include atenolol, candesartan and alpha methyldopa
  2. Current smoking or ceased within the last 3 years
  3. Chronic kidney disease which is the only categorical variable is expressed in number (percentage)
  4. SBP systolic blood pressure; DBP diastolic blood pressure
  5. eGFR estimated glomerular filtration rate using the modification of diet in renal disease equation; HDL-c high density lipoprotein cholesterol; LDL-c low density lipoprotein cholesterol
  6. a Expressed as the average of the second and third measurements